

Appendix 1. Content and rationale of the DA

Content	Pages	Rationale/Reference
About this booklet		
Description of the decision to be considered Explanation of the target population Instructions on the use of the booklet	1–3	<i>IPDASi Qualifying Criteria: The patient decision aid explicitly states the decision that needs to be considered (index decision).</i>
What is schizophrenia?		
Objective information about schizophrenia, such as symptoms, recovery as a goal, treatment, and course Explanation for non-recommendations on this DA, including discontinuation of medication	3–7	<i>IPDASi Qualifying Criteria: The patient decision aid describes the health condition or problem for which the index decision is required.</i> - Leamy et al. Br J Psychiatry. 199: 445–452, 2011. - Gardener et al. Am J Psychiatry. 167: 686–693, 2010.
A: Monotherapy		
Step 1: Further treatment options		
Options provided: Option 1: To continue the current high-dose antipsychotics Option 2: To reduce to the standard dose	9–13	<i>IPDASi Qualifying Criteria: The patient decision aid describes the options available for the index decision.</i>
Step 2: Comparing the pros and cons of each option		
A table comparing the options (advantages and disadvantages)	14	<i>IPDASi Qualifying Criteria: The patient decision aid describes the positive features of each option.</i> <i>IPDASi Qualifying Criteria: The patient decision aid describes the negative features of each option.</i> - Gardener et al. Am J Psychiatry. 167: 686–693, 2010. - Watanabe. Nervous system agents in Current Drug Therapy, NANKO-DO, 2021 (in Japanese).
Step 3: Comparing the consequences of each option		
Pictorial diagrams of the recurrence rates for each option	15	<i>IPDASi Qualifying Criteria: The patient decision aid describes what it is like to experience the consequences of the options.</i> -Tani, et al. Neuropsychopharmacology. 45:887–901, 2020.
Step 4: Value clarification		
A value-clarification exercise with a 5-point Likert scale	16	<i>IPDASi Qualifying Criteria: The patient decision aid asks patients to identify which positive and negative features of the options are important to them.</i>
Step 5: Preparation for shared decision making		
Memo field to prepare for decision-making consultation	17	<i>IPDASi Qualifying Criteria: The patient decision aid includes tools such as worksheets or lists of questions to use when discussing options with a practitioner.</i>
A: Combined use of two antipsychotic drugs		
Step 1: Further treatment options		
Options provided: Option 1: To continue the current two antipsychotics. Option 2: To shift to monotherapy	18–21	<i>IPDASi Qualifying Criteria: The patient decision aid describes the options available for the index decision.</i>

Appendix 1. Continued

Step 2: Comparing advantages and disadvantages of each option

A table comparing options (advantages and disadvantages)	22	<p><i>IPDASi Qualifying Criteria: The patient decision aid describes the positive features of each option.</i></p> <p><i>IPDASi Qualifying Criteria: The patient decision aid describes the negative features of each option.</i></p> <p>- Gardener et al. Am J Psychiatry. 167: 686–693, 2010.</p> <p>- Watanabe. Nervous system agents in Current Drug Therapy, NANKO-DO, 2021 (in Japanese)</p>
--	----	--

Step 3: Comparing the consequences of each option

Pictorial diagrams of the recurrence rates for each option	23	<p><i>IPDASi Qualifying Criteria: The patient decision aid describes what it is like to experience the consequences of the options.</i></p> <p>-Matsui, et al. Schizophr Res. 209:50–57, 2019.</p>
--	----	--

Step 4: Value clarification

A value-clarification exercise with a 5-point Likert scale	24	<p><i>IPDASi Qualifying Criteria: The patient decision aid asks patients to identify which positive and negative features of the options are important to them.</i></p>
--	----	---

Step 5: Preparation for shared decision making

Memo field to prepare for decision-making consultation	25	<p><i>IPDASi Qualifying Criteria: The patient decision aid includes tools such as worksheets or lists of questions to use when discussing options with a practitioner.</i></p>
--	----	--

Appendices

<ul style="list-style-type: none"> - Chlorpromazine-based dose - Side effects of antipsychotics - Recovery - Coping strategies to promote recovery - Details of side effects of antipsychotics 	26-32	<p>Chlorpromazine-based dose:</p> <p>-Inagaki and Inada. Japanese Journal of Clinical Pharmacology. 18:1457–1480, 2015 (in Japanese).</p> <p>-Inagaki and Inada. Japanese Journal of Clinical Pharmacology. 20:89–97, 2017 (in Japanese).</p> <p>Side effects:</p> <p>-Watanabe. Nervous system agents in Current Drug Therapy, NANKO-DO, 2021 (in Japanese).</p> <p>Recovery/Coping strategies to promote recovery.</p> <p>-Yamaguhi and Kumakura. Journal of Clinical and Experimental Medicine (IGAKU NO AYUMI). 261: 941-948, 2017 (in Japanese).</p> <p>-Leamy et al. Br J Psychiatry. 199-:445–452, 2011.</p> <p>Details of side effects of antipsychotics</p> <p>-Uchida et al. transl. Talor et al. The Maudsley Prescribing Guidelines in Psychiatry 13th Edition, Wiley Publishing Japan, 2019 (in Japanese).</p>
---	-------	---